JP2013507107A5 - - Google Patents

Download PDF

Info

Publication number
JP2013507107A5
JP2013507107A5 JP2012532489A JP2012532489A JP2013507107A5 JP 2013507107 A5 JP2013507107 A5 JP 2013507107A5 JP 2012532489 A JP2012532489 A JP 2012532489A JP 2012532489 A JP2012532489 A JP 2012532489A JP 2013507107 A5 JP2013507107 A5 JP 2013507107A5
Authority
JP
Japan
Prior art keywords
recombinant mva
hiv
mva
expression cassette
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012532489A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013507107A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/006114 external-priority patent/WO2011042180A1/en
Publication of JP2013507107A publication Critical patent/JP2013507107A/ja
Publication of JP2013507107A5 publication Critical patent/JP2013507107A5/ja
Withdrawn legal-status Critical Current

Links

JP2012532489A 2009-10-08 2010-10-06 Hivに対するヒトにおける広範なt細胞応答の生成 Withdrawn JP2013507107A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24964409P 2009-10-08 2009-10-08
US61/249,644 2009-10-08
EP10001264 2010-02-08
EP10001264.0 2010-02-08
PCT/EP2010/006114 WO2011042180A1 (en) 2009-10-08 2010-10-06 Generation of a broad t-cell response in humans against hiv

Publications (2)

Publication Number Publication Date
JP2013507107A JP2013507107A (ja) 2013-03-04
JP2013507107A5 true JP2013507107A5 (enExample) 2013-11-07

Family

ID=46396898

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012532489A Withdrawn JP2013507107A (ja) 2009-10-08 2010-10-06 Hivに対するヒトにおける広範なt細胞応答の生成

Country Status (11)

Country Link
US (1) US20120135032A1 (enExample)
EP (1) EP2486138A1 (enExample)
JP (1) JP2013507107A (enExample)
KR (1) KR20120093941A (enExample)
CN (1) CN102656271A (enExample)
AU (1) AU2010305030A1 (enExample)
CA (1) CA2767924A1 (enExample)
EA (1) EA201270108A1 (enExample)
MX (1) MX2012002531A (enExample)
SG (1) SG178909A1 (enExample)
WO (1) WO2011042180A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
AU2014231229A1 (en) * 2013-03-15 2015-09-17 Bavarian Nordic A/S Single high dose of MVA induces a protective immune response in neonates and infants
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
US11980663B2 (en) 2015-07-08 2024-05-14 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
WO2017139065A1 (en) 2016-02-08 2017-08-17 American Gene Technologies International Inc. Hiv vaccination and immunotherapy
EP3481418A4 (en) 2016-07-08 2020-03-11 American Gene Technologies International Inc. PRE-IMMUNIZATION AND IMMUNOTHERAPY OF HIV
US20220249653A1 (en) * 2019-06-27 2022-08-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for detecting hiv latency, treating hiv infection, and reversing hiv latency
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787901A (fr) 1971-09-11 1972-12-18 Freistaat Bayern Represente Pa Vaccin antivariolique
CA2392877C (en) 1999-12-23 2011-11-15 Tomas Hanke Improvements in or relating to immune responses to hiv
CN1312171C (zh) * 2000-07-14 2007-04-25 宾夕法尼亚州立大学托管会 可编码hiv辅助蛋白的dna疫苗
UA76731C2 (uk) * 2000-11-23 2006-09-15 Баваріан Нордік А/С Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
DE60205388T2 (de) 2001-12-10 2006-03-30 Bavarian Nordic A/S Poxvirus-enthaltende zusammensetzungen und verfahren zu ihrer herstellung
US7501127B2 (en) * 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
CN1982332A (zh) * 2002-05-16 2007-06-20 巴法里安诺迪克有限公司 Hiv调节/辅助蛋白的融合蛋白
DK1506301T3 (da) 2002-05-16 2014-07-21 Bavarian Nordic As Rekombinant poxvirus, der udtrykker homologe gener, der er indsat i poxvirusgenomet
US20060029619A1 (en) 2002-05-16 2006-02-09 Paul Howley Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
JP5122983B2 (ja) 2005-02-24 2013-01-16 メディカル リサーチ カウンシル Hivcon:hiv免疫原及びその使用
ES2281252B1 (es) 2005-07-27 2009-02-16 Consejo Superior De Investigaciones Cientificas Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
JP2010522761A (ja) 2007-03-26 2010-07-08 インターナショナル エイズ バクシーン イニシアティブ 改変mvaウイルスhiv−1ベクターを用いて免疫応答を誘発する方法
US8268327B2 (en) * 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
WO2009056535A2 (en) * 2007-10-29 2009-05-07 Genimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen

Similar Documents

Publication Publication Date Title
JP2013507107A5 (enExample)
AU2018267669B2 (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
JP2012509340A5 (enExample)
ES2396376T5 (es) Sitios intergénicos entre genes conservados en el genoma del virus vaccinia de vaccinia Ankara modificado (MVA)
Earl et al. Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate
EA201270108A1 (ru) Формирование полиспецифического t-клеточного ответа против вич у человека
JP6177981B2 (ja) 迅速かつ持続的な免疫学的治療法
WO2011047324A1 (en) Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
ES2399875T3 (es) Composiciones de vacunas de ADN y procedimientos para su uso
Mattapallil et al. Systemic vaccination prevents the total destruction of mucosal CD4 T cells during acute SIV challenge
WO2013026452A1 (en) Method for removing immunosuppresive properties of hiv envelope glycoproteins
WO2007137591A3 (en) Hiv vaccine
Haut et al. Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine
Chen et al. Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B′
Xu et al. Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques
WO2013010300A1 (zh) 四种及四种以上载体的hiv组合疫苗及应用
BIBERFELD et al. Protection against human immunodeficiency virus type 2 and simian immunodeficiency virus in macaques vaccinated against human immunodeficiency virus type 2
Seth et al. Development of Indian HIV-1 Subtype C Vaccine Candidates
Nelson et al. The influence of Influenza: is the Influenza vaccine as useful as we thought?
Peng CONSTRUCTION AND CHARACTERIZATION OF REPLICATION
McKenna Characterization and immunogenicity of recombinant rhabdoviral vaccine vectors expressing HIV-1 and SIV envelope proteins
OA18541A (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
NZ767061A (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
NZ730841B2 (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
HK1238577B (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection